Trial Profile
The Effects of Sativex on Neurocognitive and Behavioural Function in Adults With Attention-deficit-Hyperactivity Disorder; The EMA-C Study (Experimental Medicine in ADHD - Cannabinoids)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Oct 2020
Price :
$35
*
At a glance
- Drugs Nabiximols (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Acronyms EMA-C Study
- 22 Oct 2020 Status changed from recruiting to completed.
- 08 Oct 2014 New trial record